Shandong Buchang Pharmaceuticals Co., Ltd. (603858.SS)
CNY 16.74
(-0.71%)
CNY 16.74
(-0.71%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 436.01 Million CNY | -45.48% |
| 2022 | 1.92 Billion CNY | 10.27% |
| 2021 | 1.74 Billion CNY | -26.11% |
| 2020 | 2.36 Billion CNY | -2.62% |
| 2019 | 2.42 Billion CNY | 6.99% |
| 2018 | 2.27 Billion CNY | 29.14% |
| 2017 | 1.75 Billion CNY | -10.88% |
| 2016 | 1.97 Billion CNY | -47.3% |
| 2015 | 3.74 Billion CNY | 140.28% |
| 2014 | 1.55 Billion CNY | 8.67% |
| 2013 | 1.43 Billion CNY | -4.37% |
| 2012 | 1.49 Billion CNY | 7.59% |
| 2011 | 1.39 Billion CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 211.6 Million CNY | -4.09% |
| 2024 Q3 | 185.33 Million CNY | -12.42% |
| 2024 Q1 | 220.61 Million CNY | 1290.59% |
| 2023 Q2 | 358.7 Million CNY | -30.84% |
| 2023 Q4 | 15.86 Million CNY | -93.48% |
| 2023 Q3 | 243.2 Million CNY | -32.2% |
| 2023 Q1 | 518.68 Million CNY | 117.73% |
| 2023 FY | 1.05 Billion CNY | -45.48% |
| 2022 FY | 1.92 Billion CNY | 10.27% |
| 2022 Q1 | 530.71 Million CNY | 384.9% |
| 2022 Q2 | 464.39 Million CNY | -12.5% |
| 2022 Q3 | 554.01 Million CNY | 19.3% |
| 2022 Q4 | -2.92 Billion CNY | -628.09% |
| 2021 FY | 1.74 Billion CNY | -26.11% |
| 2021 Q4 | 109.44 Million CNY | -77.13% |
| 2021 Q3 | 478.65 Million CNY | -30.12% |
| 2021 Q2 | 684.92 Million CNY | 44.29% |
| 2021 Q1 | 474.68 Million CNY | -21.58% |
| 2020 FY | 2.36 Billion CNY | -2.62% |
| 2020 Q3 | 666.71 Million CNY | -8.42% |
| 2020 Q4 | 605.31 Million CNY | -9.21% |
| 2020 Q2 | 728.05 Million CNY | 99.31% |
| 2020 Q1 | 365.28 Million CNY | -44.04% |
| 2019 Q2 | 724.77 Million CNY | 95.92% |
| 2019 FY | 2.42 Billion CNY | 6.99% |
| 2019 Q4 | 652.76 Million CNY | -4.21% |
| 2019 Q3 | 681.48 Million CNY | -5.97% |
| 2019 Q1 | 369.92 Million CNY | -52.95% |
| 2018 Q4 | 786.18 Million CNY | 30.16% |
| 2018 Q1 | 281.43 Million CNY | -27.15% |
| 2018 FY | 2.27 Billion CNY | 29.14% |
| 2018 Q2 | 598.72 Million CNY | 112.74% |
| 2018 Q3 | 604 Million CNY | 0.88% |
| 2017 Q3 | 538.4 Million CNY | -5.61% |
| 2017 Q2 | 570.41 Million CNY | 116.93% |
| 2017 Q1 | 262.95 Million CNY | -54.75% |
| 2017 FY | 1.75 Billion CNY | -10.88% |
| 2017 Q4 | 386.29 Million CNY | -28.25% |
| 2016 Q3 | 729.95 Million CNY | 52.69% |
| 2016 Q1 | 183.7 Million CNY | -71.44% |
| 2016 Q4 | 581.07 Million CNY | -20.4% |
| 2016 FY | 1.97 Billion CNY | -47.3% |
| 2016 Q2 | 478.05 Million CNY | 160.23% |
| 2015 FY | 3.74 Billion CNY | 140.28% |
| 2015 Q4 | 643.2 Million CNY | 0.0% |
| 2014 FY | 1.55 Billion CNY | 8.67% |
| 2013 FY | 1.43 Billion CNY | -4.37% |
| 2012 FY | 1.49 Billion CNY | 7.59% |
| 2011 FY | 1.39 Billion CNY | 0.0% |